Literature DB >> 19951318

Status of blood banking and the blood supply in Afghanistan.

M Tayyeb Ayyoubi1, Terri Konstenius, Jeffrey C McCullough, Ted Eastlund, Mary Clay, Robert Bowman, Ahmad Masoud Rahmani, William Riley, Jeffrey McCullough.   

Abstract

BACKGROUND: As a result of more than 20 years of war in Afghanistan, its blood supply system has been damaged. We carried out an assessment of that blood supply system to determine the type and extent of assistance needed to increase blood availability and safety. STUDY DESIGN AND METHODS: An assessment tool was developed, daily activities in Afghanistan were observed, and key personnel were interviewed.
RESULTS: Because there was no donor recruitment organization, most blood was obtained by the family replacement system. There was an inadequate supply of stored blood, which led to use of blood before screening test results for transfusion-transmitted disease were complete. Whole blood was provided but blood components were not produced. Blood was tested intermittently for human immunodeficiency virus Types 1 and 2, hepatitis B surface antigen, hepatitis C virus, and syphilis using agglutination-based screening methods.
CONCLUSIONS: A dedicated staff is in place but to strengthen the blood supply system in Afghanistan, it will be important to address infrastructure and facilities, organization, standard operating methods, supplies and equipment, training, quality assurance, and transfusion medicine education.

Entities:  

Mesh:

Year:  2009        PMID: 19951318     DOI: 10.1111/j.1537-2995.2009.02485.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  The status of blood safety in ECO member states.

Authors:  Fariba Seighali; Nasim S Hosseini Divkolaye; Ebrahim Koohi; Ali A Pourfathollah; Ahmad M Rahmani
Journal:  Blood Transfus       Date:  2015-07-17       Impact factor: 3.443

2.  Blood safety concerns in the Eastern Mediterranean region.

Authors:  Abdol Majid Cheraghali
Journal:  Hepat Mon       Date:  2011-06       Impact factor: 0.660

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.